William R. Shepard, a director at CME Group (NASDAQ:CME), completed two stock purchases on March 26, 2026, that together totaled $437,101, according to a Securities and Exchange Commission Form 4 filing. The transactions were executed at $297.38 per share, a level close to the companys prevailing market quote of $297.60.
The filing shows Shepard acquired 1,407.78 shares of Common Stock Class A indirectly through a trust and purchased 62.06 shares directly. After these buys, Shepards direct ownership stands at 2,539.45 shares, while his indirect holdings total 260,117.54 shares.
CME Group, the derivatives exchange operator, has a market capitalization of $108 billion and a reported price-to-earnings ratio of 26.56. Independent analysis from InvestingPro, cited in the filing summary, rates the stock as appearing slightly overvalued relative to its Fair Value. The same analysis assigns CME a "GOOD" financial health score and notes the company has paid dividends for 24 consecutive years. Those items are highlighted as part of the InvestingPro toolkit, which also offers ProTips and comprehensive Pro Research Reports covering more than 1,400 U.S. equities.
In addition to the insider activity, CME has reported several recent business developments. The exchange recorded a new high for open interest in its U.S. Treasury futures and options, exceeding 36.3 million contracts and topping the previous record set in November 2025. Management has also announced plans to begin 24/7 trading for its cryptocurrency futures and options on May 29, pending regulatory approval. That move follows a reported $3 trillion in notional cryptocurrency trading volume during 2025.
The company experienced temporary technical disruptions that caused a pause in trading on its Globex metals and natural gas futures and options markets. CME said it worked to address the issues and trading resumed shortly after the halt.
From the equity research side, Raymond James reiterated an Outperform rating on CME Group and maintained a $310.00 price target. The firm also pointed to a decline in open interest at competitor FMX, a dynamic Raymond James suggested could affect market behavior.
This report presents transaction and corporate developments as disclosed in regulatory filings and company statements. It does not provide investment advice.